ARTBIO
- Company typePrivate
- Founded2021
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What ARTBIO does
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company developing a new class of alpha radioligand therapies (ART) for cancer treatment, founded in 2021 and headquartered in Cambridge, Massachusetts. The company's core technology centers on the use of lead-212 (212Pb) as an in vivo generator of alpha-emitting bismuth-212, which the company positions as offering potentially improved efficacy and safety compared to existing beta radioligand therapies. The proprietary AlphaDirect™ platform supports the design, manufacturing, and decentralized distribution of lead-212 based therapies, and the company's lead program AB001 (212Pb-NG001) is currently in Phase 1 clinical trials (the ARTISAN study) for metastatic castration-resistant prostate cancer (mCRPC) at U.S. clinical trial sites including BAMF Health.
ARTBIO firmographics
Firmographics- Name
- ARTBIO
- Legal name
- ARTBIO, Inc.
- Website
- https://artbio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
ARTBIO industry classification
Industry- Product category
- Radiopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
- akta.pro secondary industries
- Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF), Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC)
Keywords
Where ARTBIO is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
ARTBIO business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: As a clinical-stage company, ARTBIO currently has no revenue. The company is developing targeted alpha radioligand therapies for cancer treatment and will generate revenue through the sale of approved radiopharmaceutical products upon successful clinical development and regulatory approval.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
ARTBIO product offering
Product offeringCore offering
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company developing a new class of alpha radioligand therapies (ART) for cancer treatment using Lead-212 (212Pb) as the alpha-emitting isotope. The company's lead program AB001 (212Pb-NG001) targets metastatic castration-resistant prostate cancer and is currently in Phase 1 clinical trials, with additional pipeline programs targeting TNBC, HNSCC, NSCLC, pancreatic cancer, and other solid tumors. The company builds a comprehensive ecosystem including proprietary AlphaDirect™ isotope technology and a decentralized manufacturing network to design, manufacture, and distribute its radioligand therapies.
Product overview
ARTBIO is a clinical-stage radiopharmaceutical company developing a new class of alpha radioligand therapies (ART) for cancer treatment. The company's differentiated pipeline includes lead program AB001 (a Lead-212 based therapy for prostate cancer currently in Phase 1), supported by its proprietary AlphaDirect™ isotope production technology. ARTBIO's approach utilizes Lead-212 as an ideal alpha-emitting isotope and builds a comprehensive manufacturing ecosystem to enable decentralized production of radiopharmaceuticals. Additional pipeline programs include ABD (TNBC, HNSCC), ABA (NSCLC, Pancreas), ABC (Multiple Solid Tumors), and HEARTS (Multiple Solid Tumors), with many more programs in development.
Differentiator
Problem solved
Functional benefit
Brands
- AlphaDirect™: Proprietary isotope technology developed by ARTBIO for producing alpha radioligand therapies.
Products and services
- AB001 (212Pb-NG001) Lead alpha radioligand therapy program using Lead-212 (212Pb) conjugated to a PSMA-targeting ligand for treatment of metastatic castration-resistant prostate cancer (mCRPC). Currently in Phase 1 clinical trials (ARTISAN trial) enrolling both treatment-naïve and 177Lu-PSMA-experienced patients.
- AlphaDirect™ Technology Platform Proprietary isotope production technology platform for the decentralized manufacturing of alpha radioligand therapies using Lead-212. Underpins ARTBIO's lead-212-based radiopharmaceutical portfolio.
- ABD Non-clinical stage alpha radioligand therapy candidate targeting triple-negative breast cancer (TNBC) and head and neck squamous cell carcinoma (HNSCC).
- ABA Non-clinical stage alpha radioligand therapy candidate targeting non-small cell lung cancer (NSCLC) and pancreatic cancer.
- ABC Discovery-stage alpha radioligand therapy candidate targeting multiple solid tumor types.
- HEARTS Discovery-stage alpha radioligand therapy program targeting multiple solid tumor types.
Companies that use ARTBIO
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
ARTBIO technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ARTBIO partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered major and core.
- OncoinventmajorOncoinvent announced an agreement with ARTBIO to collaborate on radiopharma laboratory facilities, supporting ARTBIO's manufacturing infrastructure development.
- 3B PharmaceuticalsmajorARTBIO entered into a licensing and research partnership with 3B Pharmaceuticals to advance a first-in-class alpha radioligand therapy for solid tumors. This partnership brings together complementary expertise in radiopharmaceutical development.
- Thor MedicalcoreThor Medical and ARTBIO signed a strategic long-term supply agreement for Thorium-228, a critical isotope for ARTBIO's alpha radioligand therapies. This ensures reliable supply of key radioactive material.
- University of Oslo / Oslo Science ParkcoreARTBIO expanded its radiopharmaceutical R&D capabilities with a move to Oslo Science Park. The company has roots in groundbreaking research conducted at the University of Oslo and Norway's Radium Hospital.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
ARTBIO competitors and assessment
Company assessmentBroad incumbents
- Lantheus Holdings: Established radiopharmaceutical company with portfolio including diagnostic radiopharmaceuticals and prostate cancer imaging agents (Pylarify). Competes in the broader nuclear medicine ecosystem serving the same clinical sites and patient populations ARTBIO targets.
- Fusion Pharmaceuticals: Clinical-stage radiopharmaceutical company developing targeted alpha therapies (actinium-225). Acquired by AstraZeneca in 2024 for approximately $2.4B, validating M&A appetite for alpha radioligand platforms and representing a potential exit benchmark for ARTBIO.
- ITM Isotope Technologies Munich: Radiopharmaceutical company specializing in medical radioisotopes and targeted radionuclide therapies, including lutetium-177-based products. Competes in the broader radioligand therapy space and shares ARTBIO's manufacturing complexity around isotope production and supply.
- Bayer (Xofigo): Acquired Xofigo (radium-223) — the first commercial alpha-emitting therapy — via Algeta. ARTBIO's scientific co-founders Roy Larsen and Øyvind Bruland invented Xofigo, establishing a direct lineage between Bayer's alpha therapy franchise and ARTBIO's platform.
- Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with approved PSMA imaging agent (Illuccix) and development pipeline including therapeutic radioligands. Targets the same prostate cancer patient population as ARTBIO's lead AB001 program.
- Novartis (Pluvicto / Radioligand Therapy): Pharma incumbent whose Pluvicto (177Lu-PSMA-617) established the radioligand therapy market in prostate cancer, generating significant commercial revenue. ARTBIO's CEO Emanuele Ostuni was previously at Novartis Oncology, and ARTBIO targets the same prostate cancer indication with a differentiated alpha-emitting approach.
Emerging players
- Advancell: Emerging player developing lead-212-based radiopharmaceuticals in clinical trials, identified in ARTBIO data as a peer competing in the same lead-212 modality and overlapping target antigens.
Direct peers
- Orano Med: Subsidiary of Orano Group developing lead-212 (212Pb) alpha radioligand therapies for cancer. Identified in ARTBIO data as a direct lead-212 competitor with clinical-stage programs targeting PSMA and other tumor-associated antigens.
- Perspective Therapeutics: Clinical-stage radiopharmaceutical company developing lead-212-based alpha radioligand therapies (212Pb-VMT-α-NET for neuroendocrine tumors and 212Pb-VMT01 for melanoma). Identified in ARTBIO data as a direct lead-212 competitor targeting overlapping tumor antigens.
Regional players
- Oncoinvent: Norwegian radiopharmaceutical company developing alpha-emitting therapies (radium-224). Already partners with ARTBIO on radiopharma laboratory facilities, providing manufacturing infrastructure support; shares ARTBIO's Norwegian scientific heritage and radionuclide therapy focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ARTBIO social profiles
Digital presenceARTBIO financial estimates
Financial estimateRevenue estimate
Valuation estimate
ARTBIO leadership team
Management profileNumber of profiles
Profiles9 records
ARTBIO subsidiaries and ownership
Company hierarchySubsidiaries4 records
ARTBIO funding detail
Funding detailFunding overview
Funding rounds3 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ARTBIO M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ARTBIO
What does ARTBIO do?
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company developing a new class of alpha radioligand therapies (ART) for cancer treatment using Lead-212 (212Pb) as the alpha-emitting isotope. The company's lead program AB001 (212Pb-NG001) targets metastatic castration-resistant prostate cancer and is currently in Phase 1 clinical trials, with additional pipeline programs targeting TNBC, HNSCC, NSCLC, pancreatic cancer, and other solid tumors. The company builds a comprehensive ecosystem including proprietary AlphaDirect™ isotope technology and a decentralized manufacturing network to design, manufacture, and distribute its radioligand therapies.
Is ARTBIO a public or private company?
ARTBIO is a private company. It is classified as venture growth investor backed and is currently operating.
When was ARTBIO founded?
ARTBIO was founded in 2021. It employs 51 to 100 people.
Where is ARTBIO based?
ARTBIO is headquartered in Cambridge, United States, in the North America region.
How does ARTBIO make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are ARTBIO's main competitors?
Broad incumbents on record are Lantheus Holdings, Fusion Pharmaceuticals, ITM Isotope Technologies Munich, Bayer (Xofigo), Telix Pharmaceuticals and Novartis (Pluvicto / Radioligand Therapy). Advancell is listed as an emerging player. Direct peers are Orano Med and Perspective Therapeutics. Oncoinvent is listed as a regional player.
Does ARTBIO have an API?
No public API is recorded for ARTBIO.
What industry is ARTBIO in?
ARTBIO's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish). Its NAICS code is 3254 and its SIC code is 2834.